Contracts › 75A50123C00050
75A50123C00050: Venatorx Pharmaceuticals: New Antibiotics to Treat Drug-Resistant Gram-Negative Bacteria Including Public Health Pathogens.
Awarded to Basilea Pharmaceutica International Ltd, Allschwil by Office of Assistant Secretary for Preparedness and Response.
$45.2Mobligated
$191.9Mpotential value
31 December 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50123C00050 |
|---|---|
| Awardee | Basilea Pharmaceutica International Ltd, Allschwil |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN13 Health R&D Services; Health Care Services; Experimental Development |
| Place of performance | PA |
| Offers received | 1 |
| Period of performance | 15 September 2023 to 31 December 2027 |
| Potential end | 31 December 2029 |
| Estimated recompete solicitation | ~Q3 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 14 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record